Pharmaand Drug Patent Portfolio

Pharmaand owns 1 orange book drug protected by 12 US patents Given below is the list of Pharmaand's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10130636 High dosage strength tablets of rucaparib 17 Aug, 2035
Active
US9987285 High dosage strength tablets of rucaparib 17 Aug, 2035
Active
US8859562 Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer 04 Aug, 2031
Active
US10278974 Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one 10 Feb, 2031
Active
US8754072 Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one 10 Feb, 2031
Active
US9045487 Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one 10 Feb, 2031
Active
US9861638 Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one 10 Feb, 2031
Active
US8071579 DNA damage repair inhibitors for the treatment of cancer 12 Aug, 2027
Active
US8143241 DNA damage repair inhibitors for treatment of cancer 12 Aug, 2027
Active
US7351701 Therapeutic compounds 23 Jul, 2024 Expired
US7531530 Therapeutic compounds 23 Jul, 2024 Expired
US6495541 Tricyclic inhibitors of poly(ADP-ribose) polymerases 22 Nov, 2023 Expired


Given below is the list of recent legal activities going on the following drug patents of Pharmaand.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 16 Nov, 2022 US9045487
Payment of Maintenance Fee, 4th Year, Large Entity 26 Oct, 2022 US10278974
Payment of Maintenance Fee, 4th Year, Large Entity 04 May, 2022 US10130636
Payment of Maintenance Fee, 8th Year, Large Entity 01 Dec, 2021 US8754072
Payment of Maintenance Fee, 4th Year, Large Entity 17 Nov, 2021 US9987285
Payment of Maintenance Fee, 4th Year, Large Entity 23 Jun, 2021 US9861638
Change in Power of Attorney (May Include Associate POA) 05 Mar, 2021 US10130636
Correspondence Address Change 04 Mar, 2021 US9987285
Change in Power of Attorney (May Include Associate POA) 04 Mar, 2021 US9987285
Correspondence Address Change 04 Mar, 2021 US10130636
Change in Power of Attorney (May Include Associate POA) 26 Feb, 2021 US10278974
Change in Power of Attorney (May Include Associate POA) 26 Feb, 2021 US9045487
Change in Power of Attorney (May Include Associate POA) 26 Feb, 2021 US8754072
Change in Power of Attorney (May Include Associate POA) 26 Feb, 2021 US9861638
Correspondence Address Change 25 Feb, 2021 US9045487


Pharmaand's Drug Patent Litigations

Pharmaand's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 11, 2011, against patent number US8859562. The petitioner , challenged the validity of this patent, with Thomas Helleday as the respondent. Click below to track the latest information on how companies are challenging Pharmaand's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8859562 October, 2011 Decision
(25 Mar, 2014)
Thomas Helleday


Pharmaand Drug Patents' Oppositions Filed in EPO

Pharmaand drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 13, 2012, by Strawman Limited. This opposition was filed on patent number EP04743564A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP16183844A Apr, 2020 Generics [UK] Ltd Granted and Under Opposition
EP11708094A Jun, 2017 Hexal AG / Sandoz International GmbH Granted and Under Opposition
EP11708094A Jun, 2017 Hamm&Wittkopp Patentanwälte PartmbB Granted and Under Opposition
EP04798705A May, 2012 Adams, Harvey Vaughan John Opposition procedure closed
EP04798705A May, 2012 STRAWMAN LIMITED Opposition procedure closed
EP04743564A Apr, 2012 Adams, Harvey Vaughan John Patent maintained as amended
EP04743564A Apr, 2012 STRAWMAN LIMITED Patent maintained as amended


Pharmaand's Family Patents

Pharmaand drugs have patent protection in a total of 43 countries. It's US patent count contributes only to 17.2% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Pharmaand Drug List

Given below is the complete list of Pharmaand's drugs and the patents protecting them.


1. Rubraca

Rubraca is protected by 12 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10130636 High dosage strength tablets of rucaparib 17 Aug, 2035
(10 years from now)
Active
US9987285 High dosage strength tablets of rucaparib 17 Aug, 2035
(10 years from now)
Active
US8859562 Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer 04 Aug, 2031
(6 years from now)
Active
US10278974 Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one 10 Feb, 2031
(6 years from now)
Active
US8754072 Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one 10 Feb, 2031
(6 years from now)
Active
US9045487 Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one 10 Feb, 2031
(6 years from now)
Active
US9861638 Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one 10 Feb, 2031
(6 years from now)
Active
US8071579 DNA damage repair inhibitors for the treatment of cancer 12 Aug, 2027
(2 years from now)
Active
US8143241 DNA damage repair inhibitors for treatment of cancer 12 Aug, 2027
(2 years from now)
Active
US7351701 Therapeutic compounds 23 Jul, 2024
(3 months ago)
Expired
US7531530 Therapeutic compounds 23 Jul, 2024
(3 months ago)
Expired
US6495541 Tricyclic inhibitors of poly(ADP-ribose) polymerases 22 Nov, 2023
(a year ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rubraca's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List